Scott M Palmer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3051533/publications.pdf

Version: 2024-02-01

224 papers

12,828 citations

62 h-index

18482

30087 103 g-index

228 all docs 228 docs citations

times ranked

228

10191 citing authors

#	Article	IF	CITATIONS
1	Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant. JAMA Surgery, 2022, 157, e215856.	4.3	10
2	Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Annals of the American Thoracic Society, 2022, 19, 981-990.	3.2	14
3	Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort. Lung, 2022, 200, 11-18.	3.3	2
4	E-cigarette and food flavoring diacetyl alters airway cell morphology, inflammatory and antiviral response, and susceptibility to SARS-CoV-2. Cell Death Discovery, 2022, 8, 64.	4.7	9
5	LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 61.	3.6	20
6	Rare and Common Variants in <i>KIF15</i> Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 56-69.	5.6	25
7	Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease. JAMA Network Open, 2022, 5, e2218189.	5.9	18
8	A three-tier system for evaluation of organ procurement organizations' willingness to pursue and utilize nonideal donor lungs. American Journal of Transplantation, 2021, 21, 1269-1277.	4.7	7
9	Advances in Human Lung Transplantation. Annual Review of Medicine, 2021, 72, 135-149.	12.2	12
10	Risk factors for mortality in lung transplant recipients aged ≥65 years: A retrospective cohort study of 5,815 patients in the scientific registry of transplant recipients. Journal of Heart and Lung Transplantation, 2021, 40, 42-55.	0.6	20
11	Bacteremia in solid organ transplant recipients as compared to immunocompetent patients: Acute phase cytokines and outcomes in a prospective, matched cohort study. American Journal of Transplantation, 2021, 21, 2113-2122.	4.7	10
12	Primary graft dysfunction and healthâ€related quality of life after transplantation: The good, the bad, and the missing. American Journal of Transplantation, 2021, 21, 456-457.	4.7	1
13	Ontology-guided segmentation and object identification for developmental mouse lung immunofluorescent images. BMC Bioinformatics, 2021, 22, 82.	2.6	2
14	Evidence of Epsteinâ€Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder. Journal of Medical Virology, 2021, 93, 5040-5047.	5.0	2
15	Intragraft Hyaluronan Increases in Association With Acute Lung Transplant Rejection. Transplantation Direct, 2021, 7, e685.	1.6	O
16	Immunity to varicella, measles, and mumps in patients evaluated for lung transplantation. American Journal of Transplantation, 2021, 21, 2864-2870.	4.7	4
17	Lung Transplantation: Controversies and Evolving Concepts. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 327-328.	2.1	0
18	Correlation between BAL CXCR3 chemokines and lung allograft histopathologies: A multicenter study. American Journal of Transplantation, 2021, 21, 3401-3410.	4.7	5

#	Article	IF	Citations
19	IL-10 and class 1 histone deacetylases act synergistically and independently on the secretion of proinflammatory mediators in alveolar macrophages. PLoS ONE, 2021, 16, e0245169.	2.5	10
20	Diacetyl exposure disrupts iron homeostasis in animals and cells. Inhalation Toxicology, 2021, 33, 268-274.	1.6	2
21	Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA ₁) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respiratory Research, 2021, 8, e001026.	3.0	20
22	Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells. IScience, 2021, 24, 103412.	4.1	20
23	Amphiregulin contributes to airway remodeling in chronic allograft dysfunction after lung transplantation. American Journal of Transplantation, 2020, 20, 825-833.	4.7	18
24	Histone Deacetylase 7 in Murine Gram-Negative Acute Lung Injury. Shock, 2020, 53, 375-377.	2.1	4
25	Overview and Challenges of Bronchiolar Disorders. Annals of the American Thoracic Society, 2020, 17, 253-263.	3.2	9
26	Histone Deacetylase 7 Inhibition in a Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury. Shock, 2020, 53, 344-351.	2.1	12
27	Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Annals of the American Thoracic Society, 2020, 17, 1413-1423.	3.2	32
28	Skeletal muscle adiposity and outcomes in candidates for lung transplantation: a lung transplant body composition cohort study. Thorax, 2020, 75, 801-804.	5.6	12
29	Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. BMC Pulmonary Medicine, 2020, 20, 64.	2.0	59
30	Remote Therapy to Improve Outcomes in Lung Transplant Recipients: Design of the INSPIRE-III Randomized Clinical Trial. Transplantation Direct, 2020, 6, e535.	1.6	8
31	Thoracic Visceral Adipose Tissue Area and Pulmonary Hypertension in Lung Transplant Candidates. The Lung Transplant Body Composition Study. Annals of the American Thoracic Society, 2020, 17, 1393-1400.	3.2	9
32	Depression, Immunosuppressant Levels, and Clinical Outcomes in Postlung Transplant Recipients. International Journal of Psychiatry in Medicine, 2020, 55, 421-436.	1.8	12
33	Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry. Annals of the American Thoracic Society, 2020, 17, 699-705.	3.2	19
34	Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2020, 157, 1188-1198.	0.8	21
35	Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest, 2020, 157, 1522-1530.	0.8	14
36	Highlights from the clinical trials in organ transplantation (CTOT)-20 and CTOT-22 Consortium studies in lung transplant. American Journal of Transplantation, 2020, 20, 1489-1494.	4.7	3

#	Article	IF	Citations
37	Bronchoalveolar bile acid and inflammatory markers to identify high-risk lung transplant recipients with reflux and microaspiration. Journal of Heart and Lung Transplantation, 2020, 39, 934-944.	0.6	21
38	Identifying host microRNAs in bronchoalveolar lavage samples from lung transplant recipients infected with Aspergillus. Journal of Heart and Lung Transplantation, 2020, 39, 1228-1237.	0.6	5
39	A retrospective study of in-hospital mortality in patients with idiopathic pulmonary fibrosis between 2015 and 2018. Medicine (United States), 2020, 99, e23143.	1.0	6
40	A nonlinear relationship between visceral adipose tissue and frailty in adult lung transplant candidates. American Journal of Transplantation, 2019, 19, 3155-3161.	4.7	25
41	Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respiratory Research, 2019, 20, 227.	3.6	59
42	Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study. Journal of Heart and Lung Transplantation, 2019, 38, 1246-1256.	0.6	29
43	In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis: A US Cohort Study. Lung, 2019, 197, 699-707.	3.3	22
44	Usefulness of gene expression profiling of bronchoalveolar lavage cells in acute lung allograft rejection. Journal of Heart and Lung Transplantation, 2019, 38, 845-855.	0.6	34
45	Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respiratory Research, 2019, 20, 105.	3.6	44
46	Lung Transplant Outcomes in Patients With Pulmonary Fibrosis With Telomere-Related Gene Variants. Chest, 2019, 156, 477-485.	0.8	60
47	EGFR-Dependent IL8 Production by Airway Epithelial Cells After Exposure to the Food Flavoring Chemical 2,3-Butanedione. Toxicological Sciences, 2019, 169, 534-542.	3.1	15
48	Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome―A consensus report from the Pulmonary Council of the ISHLT. Journal of Heart and Lung Transplantation, 2019, 38, 483-492.	0.6	190
49	Decreased Antibiotic Utilization After Sinus Surgery in Cystic Fibrosis Patients With Lung Transplantation. American Journal of Rhinology and Allergy, 2019, 33, 354-358.	2.0	15
50	IL-17A Contributes to Lung Fibrosis in a Model of Chronic Pulmonary Graft-versus-host Disease. Transplantation, 2019, 103, 2264-2274.	1.0	7
51	Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction. Journal of Heart and Lung Transplantation, 2019, 38, 184-193.	0.6	12
52	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 2018, 18, 1604-1614.	4.7	205
53	Complement system in lung transplantation. Clinical Transplantation, 2018, 32, e13208.	1.6	20
54	Gene Expression Profiling of Bronchoalveolar Lavage Cells During Aspergillus Colonization of the Lung Allograft. Transplantation, 2018, 102, 986-993.	1.0	15

#	Article	IF	Citations
55	Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction after Lung Transplant. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 235-243.	5.6	45
56	Correlation between sinus and lung cultures in lung transplant patients with cystic fibrosis. International Forum of Allergy and Rhinology, 2018, 8, 389-393.	2.8	35
57	Depression, social support, and clinical outcomes following lung transplantation: a single-center cohort study. Transplant International, 2018, 31, 495-502.	1.6	30
58	Factors associated with reporting results for pulmonary clinical trials in ClinicalTrials.gov. Clinical Trials, 2018, 15, 87-94.	1.6	2
59	Neurological Sequelae and Clinical Outcomes After Lung Transplantation. Transplantation Direct, 2018, 4, e353.	1.6	24
60	Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest, 2018, 154, 1061-1069.	0.8	140
61	Pre-transplant weight loss and clinical outcomes after lung transplantation. Journal of Heart and Lung Transplantation, 2018, 37, 1443-1447.	0.6	31
62	Current challenges and opportunities in the management of antibody-mediated rejection in lung transplantation. Current Opinion in Organ Transplantation, 2018, 23, 308-315.	1.6	16
63	Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. JCI Insight, 2018, 3, .	5.0	35
64	Bronchus-associated lymphoid tissue–resident Foxp3+ T lymphocytes prevent antibody-mediated lung rejection. Journal of Clinical Investigation, 2018, 129, 556-568.	8.2	60
65	Survival Benefit of Lung Transplantation in the Modern Era of Lung Allocation. Annals of the American Thoracic Society, 2017, 14, 172-181.	3.2	91
66	An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 82-93.	5.6	185
67	The utility of 6-minute walk distance in predicting waitlist mortality for lung transplant candidates. Journal of Heart and Lung Transplantation, 2017, 36, 780-786.	0.6	16
68	Models of toxicity of diacetyl and alternative diones. Toxicology, 2017, 388, 15-20.	4.2	19
69	The Diacetyl-Exposed Human Airway Epithelial Secretome: New Insights into Flavoring-Induced Airways Disease. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 784-795.	2.9	20
70	Proteomic Analysis of Primary Human Airway Epithelial Cells Exposed to the Respiratory Toxicant Diacetyl. Journal of Proteome Research, 2017, 16, 538-549.	3.7	26
71	Antibody depletion strategy for the treatment of suspected antibodyâ€mediated rejection in lung transplant recipients: Does it work?. Clinical Transplantation, 2017, 31, e12886.	1.6	22
72	Host–Pathogen Interactions and Chronic Lung Allograft Dysfunction. Annals of the American Thoracic Society, 2017, 14, S242-S246.	3.2	16

#	Article	IF	Citations
73	Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension. Annals of the American Thoracic Society, 2017, 14, 1514-1522.	3.2	39
74	LungMAP: The Molecular Atlas of Lung Development Program. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 313, L733-L740.	2.9	162
75	Depressive symptoms and early mortality following lung transplantation: A pilot study. Clinical Transplantation, 2017, 31, e12874.	1.6	34
76	Chest Fat Quantification via CT Based on Standardized Anatomy Space in Adult Lung Transplant Candidates. PLoS ONE, 2017, 12, e0168932.	2.5	21
77	Gene Expression Profiling of Bronchoalveolar Lavage Cells Preceding a Clinical Diagnosis of Chronic Lung Allograft Dysfunction. PLoS ONE, 2017, 12, e0169894.	2.5	31
78	Danger signals in regulating the immune response to solid organ transplantation. Journal of Clinical Investigation, 2017, 127, 2464-2472.	8.2	47
79	Validation and Refinement of Chronic Lung Allograft Dysfunction Phenotypes in Bilateral and Single Lung Recipients. Annals of the American Thoracic Society, 2016, 13, 627-635.	3.2	41
80	The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia. Journal of Heart and Lung Transplantation, 2016, 35, 500-507.	0.6	30
81	High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. European Respiratory Journal, 2016, 48, 1442-1452.	6.7	110
82	Accumulation of Ubiquitin and Sequestosome-1 Implicate Protein Damage in Diacetyl-Induced Cytotoxicity. American Journal of Pathology, 2016, 186, 2887-2908.	3.8	27
83	Biobehavioral Prognostic Factors in Chronic Obstructive Pulmonary Disease. Psychosomatic Medicine, 2016, 78, 153-162.	2.0	10
84	Reduced Cerebral Perfusion Pressure during Lung Transplant Surgery Is Associated with Risk, Duration, and Severity of Postoperative Delirium. Annals of the American Thoracic Society, 2016, 13, 180-187.	3.2	36
85	Polyfunctional T-Cell Signatures to Predict Protection from Cytomegalovirus after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 78-85.	5.6	75
86	Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry. BMJ Open Respiratory Research, 2016, 3, e000108.	3.0	38
87	Chronic obstructive pulmonary disease in patients with atrial fibrillation: Insights from the ARISTOTLE trial. International Journal of Cardiology, 2016, 202, 589-594.	1.7	38
88	Special Considerations for Long-Term Survivors After Solid Organ Transplantation., 2016,, 963-978.		0
89	The Utility of Preoperative Six-Minute-Walk Distance in Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 843-852.	5.6	54
90	An assessment of human gastric fluid composition as a function of PPI usage. Physiological Reports, 2015, 3, e12269.	1.7	23

#	Article	IF	CITATIONS
91	Impaired CD8+ T cell immunity after allogeneic bone marrow transplantation leads to persistent and severe respiratory viral infection. Transplant Immunology, 2015, 32, 51-60.	1.2	9
92	Six-Minute-Walk Distance and Accelerometry Predict Outcomes in Chronic Obstructive Pulmonary Disease Independent of Global Initiative for Chronic Obstructive Lung Disease 2011 Group. Annals of the American Thoracic Society, 2015, 12, 349-356.	3.2	48
93	Development and psychometric properties of the Pulmonary-specific Quality-of-Life Scale in lung transplant patients. Journal of Heart and Lung Transplantation, 2015, 34, 1058-1065.	0.6	12
94	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respiratory Medicine, the, 2015, 3, 388-396.	10.7	69
95	Gene Expression in Obliterative Bronchiolitis-Like Lesions in 2,3-Pentanedione-Exposed Rats. PLoS ONE, 2015, 10, e0118459.	2.5	20
96	Neurocognitive Changes after Lung Transplantation. Annals of the American Thoracic Society, 2014, 11, 1520-1527.	3.2	47
97	Body Composition and Mortality after Adult Lung Transplantation in the United States. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 1012-1021.	5.6	108
98	Bronchial epithelial injury in the context of alloimmunity promotes lymphocytic bronchiolitis through hyaluronan expression. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 306, L1045-L1055.	2.9	12
99	Hyaluronan Contributes to Bronchiolitis Obliterans Syndrome and Stimulates Lung Allograft Rejection through Activation of Innate Immunity. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 556-566.	5. 6	84
100	Differential Outcomes With Early and Late RepeatÂTransplantation in the Era of the Lung Allocation Score. Annals of Thoracic Surgery, 2014, 98, 1914-1921.	1.3	35
101	Update in Lung Transplantation 2013. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 19-24.	5.6	16
102	Infections in the Immunosuppressed Host. Annals of the American Thoracic Society, 2014, 11, S211-S220.	3.2	27
103	The Effects of a Telehealth Coping Skills Intervention on Outcomes in Chronic Obstructive Pulmonary Disease. Psychosomatic Medicine, 2014, 76, 581-592.	2.0	50
104	Diacetyl Induces Amphiregulin Shedding in Pulmonary Epithelial Cells and in Experimental Bronchiolitis Obliterans. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 568-574.	2.9	33
105	The Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) equation best characterizes kidney function in patients being considered for lung transplantation. Journal of Heart and Lung Transplantation, 2014, 33, 1248-1254.	0.6	11
106	Role of C-C Motif Ligand 2 and C-C Motif Receptor 2 in Murine Pulmonary Graft-versus-Host Disease after Lipopolysaccharide Inhalations. American Journal of Respiratory Cell and Molecular Biology, 2014, 51, 810-821.	2.9	12
107	Plasma Complement Levels Are Associated with Primary Graft Dysfunction and Mortality after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1564-1567.	5. 6	30
108	Genetic Variation in the Prostaglandin E ₂ Pathway Is Associated with Primary Graft Dysfunction. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 567-575.	5.6	32

#	Article	IF	Citations
109	Neurobehavioral Functioning and Survival Following Lung Transplantation. Chest, 2014, 145, 604-611.	0.8	61
110	Impact of Forced Vital Capacity Loss on Survival after the Onset of Chronic Lung Allograft Dysfunction. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 159-166.	5.6	121
111	Allogeneic Splenocyte Transfer and Lipopolysaccharide Inhalations Induce Differential T Cell Expansion and Lung Injury: A Novel Model of Pulmonary Graft-versus-Host Disease. PLoS ONE, 2014, 9, e97951.	2.5	6
112	A Comparative Analysis of Bronchial Stricture After Lung Transplantation in Recipients With and Without Early Acute Rejection. Annals of Thoracic Surgery, 2013, 96, 1008-1018.	1.3	38
113	Use of Lung Allografts from Brain-Dead Donors after Cardiopulmonary Arrest and Resuscitation. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 466-473.	5.6	34
114	Association of Anxiety and Depression with Pulmonary-Specific Symptoms in Chronic Obstructive Pulmonary Disease. International Journal of Psychiatry in Medicine, 2013, 45, 189-202.	1.8	63
115	Using ClinicalTrials.gov to Understand the State of Clinical Research in Pulmonary, Critical Care, and Sleep Medicine. Annals of the American Thoracic Society, 2013, 10, 411-417.	3.2	8
116	Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 527-534.	5.6	529
117	Assessing the Causal Effect of Organ Transplantation on the Distribution of Residual Lifetime. Biometrics, 2013, 69, 820-829.	1.4	16
118	Correction: Novel Role for Surfactant Protein A in Gastrointestinal Graft-versus-Host Disease. Journal of Immunology, 2013, 190, 1382-1382.	0.8	0
119	Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease. Blood, 2013, 122, 3365-3375.	1.4	122
120	Latent Class Analysis Identifies Distinct Phenotypes of Primary Graft Dysfunction After Lung Transplantation. Chest, 2013, 144, 616-622.	0.8	48
121	Impact of Lung Transplantation on Recipient Quality of Life. Chest, 2013, 143, 744-750.	0.8	66
122	Implications for Human Leukocyte Antigen Antibodies After Lung Transplantation. Chest, 2013, 144, 226-233.	0.8	121
123	Racial differences in the association of CD14 polymorphisms with serum total IgE levels and allergen skin test reactivity. Journal of Asthma and Allergy, 2013, 6, 81.	3.4	7
124	An Acute Change in Lung Allocation Score and Survival After Lung Transplantation. Annals of Internal Medicine, 2013, 158, 650.	3.9	39
125	Innate Immune Responses and Bronchiolitis Obliterans Syndrome. , 2013, , 147-167.		0
126	Bronchial and Bronchiolar Fibrosis in Rats Exposed to 2,3-Pentanedione Vapors: Implications for Bronchiolitis Obliterans in Humans. Toxicologic Pathology, 2012, 40, 448-465.	1.8	79

#	Article	IF	Citations
127	Long-Term Exposure of Chemokine CXCL10 Causes Bronchiolitis-like Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 592-598.	2.9	12
128	Novel Role for Surfactant Protein A in Gastrointestinal Graft-versus-Host Disease. Journal of Immunology, 2012, 188, 4897-4905.	0.8	9
129	Clinical Year in Review I. Proceedings of the American Thoracic Society, 2012, 9, 183-189.	3.5	1
130	Montelukast for Bronchiolitis Obliterans Syndrome After Lung Transplantation: Response. Chest, 2012, 141, 276.	0.8	0
131	Protective Role of T-bet and Th1 Cytokines in Pulmonary Graft-versus-Host Disease and Peribronchiolar Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 249-256.	2.9	24
132	A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. Journal of Heart and Lung Transplantation, 2012, 31, 942-949.	0.6	53
133	Variation in <i>PTX3</i> Is Associated with Primary Graft Dysfunction after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 546-552.	5.6	68
134	Elevated Plasma Angiopoietin-2 Levels and Primary Graft Dysfunction after Lung Transplantation. PLoS ONE, 2012, 7, e51932.	2.5	28
135	Stress and coping in caregivers of patients awaiting solid organ transplantation. Clinical Transplantation, 2012, 26, 97-104.	1.6	48
136	Bronchiolitis Obliterans Syndrome. Chest, 2011, 140, 502-508.	0.8	176
137	Innate immune activation potentiates alloimmune lung disease independent of chemokine (C-X-C motif) receptor 3. Journal of Heart and Lung Transplantation, 2011, 30, 717-725.	0.6	17
138	Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. Journal of Heart and Lung Transplantation, 2011, 30, 990-996.	0.6	58
139	Innate immune activation by the viral PAMP poly I:C potentiates pulmonary graft-versus-host disease after allogeneic hematopoietic cell transplant. Transplant Immunology, 2011, 24, 83-93.	1.2	16
140	Severe Airway Epithelial Injury, Aberrant Repair and Bronchiolitis Obliterans Develops after Diacetyl Instillation in Rats. PLoS ONE, 2011, 6, e17644.	2.5	81
141	Survival after Bronchiolitis Obliterans Syndrome. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 554-555.	5.6	0
142	Osteoporosis in lung transplant candidates compared to matched healthy controls. Clinical Transplantation, 2011, 25, 426-435.	1.6	20
143	Acute Allograft Rejection: Cellular and Humoral Processes. Clinics in Chest Medicine, 2011, 32, 295-310.	2.1	69
144	The State of Genome-Wide Association Studies in Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 873-880.	5.6	36

#	Article	IF	CITATIONS
145	Obesity and Primary Graft Dysfunction after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1055-1061.	5.6	135
146	Lung-resident Mesenchymal Stromal Cells. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 968-970.	5.6	7
147	Elevated Pulmonary Artery Pressure Is a Risk Factor for Primary Graft Dysfunction Following Lung Transplantation for Idiopathic Pulmonary Fibrosis. Chest, 2011, 139, 782-787.	0.8	85
148	Effect of Single vs Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis. Chest, 2011, 140, 489-496.	0.8	18
149	Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation. Annals of Internal Medicine, 2010, 152, 761.	3.9	212
150	Lung Transplantation in Advanced COPD: Is it Worth it?. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 365-372.	2.1	10
151	Cytomegalovirus Pneumonitis Is a Risk for Bronchiolitis Obliterans Syndrome in Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1391-1396.	5.6	140
152	Survival after Bronchiolitis Obliterans Syndrome among Bilateral Lung Transplant Recipients. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 784-789.	5.6	131
153	Acute Cellular Rejection and Humoral Sensitization in Lung Transplant Recipients. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 179-188.	2.1	45
154	Construct validity of the definition of primary graft dysfunction after lung transplantation. Journal of Heart and Lung Transplantation, 2010, 29, 1231-1239.	0.6	128
155	Acute Rejection and Humoral Sensitization in Lung Transplant Recipients. Proceedings of the American Thoracic Society, 2009, 6, 54-65.	3.5	145
156	Plasma Levels of Receptor for Advanced Glycation End Products, Blood Transfusion, and Risk of Primary Graft Dysfunction. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 1010-1015.	5.6	145
157	Caregiver-assisted coping skills training for patients with COPD: background, design, and methodological issues for the INSPIRE-II study. Clinical Trials, 2009, 6, 172-184.	1.6	38
158	Progressive Multifocal Leukoencephalopathy Following Heightened Immunosuppression After Lung Transplant. Journal of Heart and Lung Transplantation, 2009, 28, 395-398.	0.6	49
159	Diagnosis and Outcome of Early Pleural Space Infection Following Lung Transplantation. Chest, 2009, 135, 484-491.	0.8	46
160	Toll-like receptors innate immunity and lung transplantation. Frontiers in Bioscience - Elite, 2009, E1, 600-604.	1.8	1
161	Lung transplantation at Duke University. Clinical Transplants, 2009, , 197-210.	0.2	7
162	Rabbit Anti-thymocyte Globulin Induction Therapy Does Not Prolong Survival After Lung Transplantation. Journal of Heart and Lung Transplantation, 2008, 27, 547-553.	0.6	50

#	Article	IF	Citations
163	Coping and quality of life in patients awaiting lung transplantation. Journal of Psychosomatic Research, 2008, 65, 71-79.	2.6	44
164	Respiratory Toxicity of Diacetyl in C57Bl/6 Mice. Toxicological Sciences, 2008, 103, 169-180.	3.1	115
165	Response to: Comments on Respiratory Toxicity of Diacetyl in C57Bl/6 Mice. Toxicological Sciences, 2008, 105, 433-434.	3.1	2
166	Alloimmune Lung Injury Induced by Local Innate Immune Activation Through Inhaled Lipopolysaccharide. Transplantation, 2007, 84, 1012-1019.	1.0	41
167	Lung transplantation in the older patient. Current Opinion in Organ Transplantation, 2007, 12, 485-490.	1.6	1
168	Survival of Lung Transplant Patients With Cystic Fibrosis Harboring Panresistant Bacteria Other Than Burkholderia cepacia, Compared With Patients Harboring Sensitive Bacteria. Journal of Heart and Lung Transplantation, 2007, 26, 834-838.	0.6	118
169	A Single-center Experience With Ganciclovir-resistant Cytomegalovirus in Lung Transplant Recipients: Treatment and Outcome. Journal of Heart and Lung Transplantation, 2007, 26, 1286-1292.	0.6	37
170	Genetics and genomics in human lung transplantation. Expert Review of Respiratory Medicine, 2007, 1, 271-278.	2.5	1
171	Lung transplantation at Duke University Medical Center. Clinical Transplants, 2007, , 99-111.	0.2	2
172	International Guidelines for the Selection of Lung Transplant Candidates: 2006 Update—A Consensus Report From the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2006, 25, 745-755.	0.6	1,080
173	Mycobacterium abscessus Chest Wall and Pulmonary Infection in a Cystic Fibrosis Lung Transplant Recipient. Journal of Heart and Lung Transplantation, 2006, 25, 985-988.	0.6	88
174	Cytokine Gene Polymorphisms Are Not Associated With Bronchiolitis Obliterans Syndrome or Survival After Lung Transplant. Journal of Heart and Lung Transplantation, 2006, 25, 1330-1335.	0.6	24
175	High Frequency of Bronchogenic Carcinoma After Single-lung Transplantation. Journal of Heart and Lung Transplantation, 2006, 25, 1297-1301.	0.6	95
176	Pathologic Correlates of Bronchiolitis Obliterans Syndrome in Pulmonary Retransplant Recipients. Chest, 2006, 129, 1016-1023.	0.8	75
177	Telephone-based coping skills training for patients awaiting lung transplantation Journal of Consulting and Clinical Psychology, 2006, 74, 535-544.	2.0	74
178	Psychosocial Issues in the Assessment and Management of Patients Undergoing Lung Transplantation. Chest, 2006, 129, 1367-1374.	0.8	54
179	Successful Bilateral Lung Transplant Outcomes in Recipients 61 Years of Age and Older. Transplantation, 2006, 81, 862-865.	1.0	22
180	Role of Flow Cytometry to Define Unacceptable HLA Antigens in Lung Transplant Recipients with HLA-Specific Antibodies. Transplantation, 2006, 81, 1049-1057.	1.0	81

#	Article	IF	Citations
181	Donor polymorphisms in Toll-like receptor-4 influence the development of rejection after renal transplantation. Clinical Transplantation, 2006, 20, 30-36.	1.6	80
182	Immune Mechanisms of Lung Allograft Rejection. Seminars in Respiratory and Critical Care Medicine, 2006, 27, 534-543.	2.1	38
183	Physician Subsidies for Tobacco Advertising. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 246-246.	5.6	8
184	Lung Transplantation: Evolving Concepts and Controversies. Seminars in Respiratory and Critical Care Medicine, 2006, 27, 439-440.	2.1	0
185	Critical Care Perspective on Immunotherapy in Lung Transplantation. Journal of Intensive Care Medicine, 2006, 21, 327-344.	2.8	12
186	Gas Exchange and Exercise Capacity Affect Neurocognitive Performance in Patients With Lung Disease. Psychosomatic Medicine, 2005, 67, 425-432.	2.0	36
187	Quality, Quantity, or Both?. Chest, 2005, 128, 1086-1087.	0.8	13
188	Acute Renal Failure after Lung Transplantation: Incidence, Predictors and Impact on Perioperative Morbidity and Mortality. American Journal of Transplantation, 2005, 5, 1469-1476.	4.7	117
189	Innate Immunity Influences Long-term Outcomes after Human Lung Transplant. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 780-785.	5.6	116
190	Emotional distress and quality of life in caregivers of patients awaiting lung transplant. Journal of Psychosomatic Research, 2005, 59, 1-6.	2.6	36
191	Pre-Transplant Panel Reactive Antibody in Lung Transplant Recipients is Associated with Significantly Worse Post-Transplant Survival in a Multicenter Study. Journal of Heart and Lung Transplantation, 2005, 24, S249-S254.	0.6	102
192	Upper Lobe Fibrosis: A Novel Manifestation of Chronic Allograft Dysfunction in Lung Transplantation. Journal of Heart and Lung Transplantation, 2005, 24, 1260-1268.	0.6	94
193	Role of Toll-Like Receptor–Driven Innate Immunity in Thoracic Organ Transplantation. Journal of Heart and Lung Transplantation, 2005, 24, 1721-1729.	0.6	34
194	Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clinical Transplantation, 2004, 18, 179-185.	1.6	29
195	Critical Care Aspects of Lung Transplantation. Journal of Intensive Care Medicine, 2004, 19, 83-104.	2.8	65
196	Early Fundoplication Prevents Chronic Allograft Dysfunction in Patients with Gastroesophageal Reflux Disease. Annals of Thoracic Surgery, 2004, 78, 1142-1151.	1.3	306
197	Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation, 2004, 77, 232-237.	1.0	175
198	Outcome of Lung Transplant Patients Admitted to the Medical ICU. Chest, 2004, 125, 1040-1045.	0.8	36

#	Article	IF	Citations
199	Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 533-542.	0.8	343
200	Gastroesophageal reflux disease in lung transplant recipients. Clinical Transplantation, 2003, 17, 363-368.	1.6	183
201	Psychiatric Disorder and Quality of Life in Patients Awaiting Lung Transplantation *. Chest, 2003, 124, 1682-1688.	0.8	73
202	The Role of Innate Immunity in Acute Allograft Rejection after Lung Transplantation. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 628-632.	5.6	167
203	Pleural Effusions in Lung Transplant Recipients: Image-guided Small-Bore Catheter Drainage. Radiology, 2003, 228, 241-245.	7.3	21
204	Lung Transplantation Exacerbates Gastroesophageal Reflux Disease *. Chest, 2003, 124, 1689-1693.	0.8	208
205	Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients: Correlation of Computed Tomography Findings With Bronchiolitis Obliterans Syndrome Stage. Journal of Thoracic Imaging, 2003, 18, 72-79.	1.5	36
206	Posttransplant Lymphoproliferative Disorder. Chest, 2003, 124, 1242-1249.	0.8	138
207	Respiratory Failure Early After Lung Transplantation. Chest, 2003, 123, 14-16.	0.8	12
208	Effects of a Telephone-Based Psychosocial Intervention for Patients Awaiting Lung Transplantation. Chest, 2002, 122, 1176-1184.	0.8	72
209	Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome Transplantation, 2002, 74, 799-804.	1.0	177
210	Is Transplant Operation Important in Determining Posttransplant Risk of Bronchiolitis Obliterans Syndrome in Lung Transplant Recipients?. Chest, 2002, 122, 1168-1175.	0.8	55
211	Treatment of refractory acute rejection in a lung transplant recipient with campath 1H Transplantation, 2002, 74, 903-904.	1.0	28
212	RESULTS OF A RANDOMIZED, PROSPECTIVE, MULTICENTER TRIAL OF MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN THE PREVENTION OF ACUTE LUNG ALLOGRAFT REJECTION1. Transplantation, 2001, 71, 1772-1776.	1.0	99
213	Lung Transplantation After Long-term Mechanical Ventilation. Chest, 2001, 119, 224-227.	0.8	51
214	Influenza Pneumonia in Lung Transplant Recipients. Chest, 2001, 119, 1277-1280.	0.8	114
215	Complications (Excluding Hyperinflation) Involving the Native Lung after Single-Lung Transplantation: Incidence, Radiologic Features, and Clinical Importance. Radiology, 2001, 218, 233-241.	7.3	46
216	SAFETY OF AEROSOLIZED AMPHOTERICIN B LIPID COMPLEX IN LUNG TRANSPLANT RECIPIENTS 12. Transplantation, 2001, 72, 545-548.	1.0	137

#	Article	IF	CITATIONS
217	Gastroesophageal Reflux as a Reversible Cause of Allograft Dysfunction After Lung Transplantation. Chest, 2000, 118, 1214-1217.	0.8	154
218	Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Annals of Thoracic Surgery, 2000, 69, 1520-1524.	1.3	100
219	SIGNIFICANCE OF BLOOD STREAM INFECTION AFTER LUNG TRANSPLANTATION: ANALYSIS IN 176 CONSECUTIVE PATIENTS1. Transplantation, 2000, 69, 2360-2366.	1.0	89
220	Rabbit Antithymocyte Globulin Decreases Acute Rejection After Lung Transplantation. Chest, 1999, 116, 127-133.	0.8	102
221	Community Respiratory Viral Infection in Adult Lung Transplant Recipients. Chest, 1998, 113, 944-950.	0.8	129
222	Minnesota multiphasic personality inventory profiles of Vietnam combat veterans with posttraumatic stress disorder and their children., 1997, 53, 847-852.		48
223	Plasma <scp>CXCL9</scp> and <scp>CXCL10</scp> at Allograft Injury Predicts Chronic Lung Allograft Dysfunction. American Journal of Transplantation, 0, , .	4.7	7
224	Genome-wide Enrichment of <i>TERT</i> Rare Variants in IPF Patients of Latino Ancestry. American Journal of Respiratory and Critical Care Medicine, 0, , .	5.6	6